Santen Pharmaceutical Co (SNPHF) Ratios
Santen Pharmaceutical Co Ratios
SNPHF's free cash flow for Q2 2026 was $4.32B. For the 2026 fiscal year, SNPHF's free cash flow was decreased by $-1.53B and operating cash flow was $5.85B. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 26 | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.58 | 2.60 | 2.54 | 2.38 | 2.39 |
| Quick Ratio | 1.99 | 1.87 | 2.08 | 1.94 | 2.01 |
| Cash Ratio | 1.07 | 0.92 | 1.02 | 0.65 | 0.87 |
| Solvency Ratio | 0.44 | 0.44 | 0.34 | 0.02 | 0.36 |
| Operating Cash Flow Ratio | 0.70 | 0.50 | 0.78 | 0.42 | 0.48 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 142.16 | 26.44 | 12.16 | 4.21 |
| Net Current Asset Value | $ 100.20B | $ 101.74B | $ 105.81B | $ 85.44B | $ 106.29B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.08 | 0.08 | 0.08 | 0.09 | 0.07 |
| Debt-to-Equity Ratio | 0.12 | 0.12 | 0.11 | 0.12 | 0.10 |
| Debt-to-Capital Ratio | 0.11 | 0.10 | 0.10 | 0.11 | 0.09 |
| Long-Term Debt-to-Capital Ratio | 0.08 | 0.08 | 0.08 | 0.09 | 0.04 |
| Financial Leverage Ratio | 1.43 | 1.42 | 1.42 | 1.43 | 1.36 |
| Debt Service Coverage Ratio | 50.68 | 25.18 | 9.85 | 1.12 | 3.80 |
| Interest Coverage Ratio | 51.92 | 22.68 | 19.48 | 21.36 | 29.68 |
| Debt to Market Cap | 0.05 | 0.05 | 0.06 | 0.07 | 0.05 |
| Interest Debt Per Share | 100.51 | 112.16 | 103.09 | 97.33 | 85.40 |
| Net Debt to EBITDA | -0.89 | -0.68 | -1.05 | -1.52 | -0.92 |
| Profitability Margins | |||||
| Gross Profit Margin | 54.40% | 55.20% | 59.18% | 59.52% | 58.81% |
| EBIT Margin | 16.19% | 16.95% | 12.68% | -1.06% | 13.83% |
| EBITDA Margin | 22.17% | 23.25% | 18.70% | 5.12% | 20.48% |
| Operating Profit Margin | 18.74% | 15.50% | 17.19% | 11.47% | 13.48% |
| Pretax Profit Margin | 15.83% | 16.27% | 9.89% | -2.08% | 13.38% |
| Net Profit Margin | 12.09% | 12.81% | 8.82% | -5.36% | 10.22% |
| Continuous Operations Profit Margin | 11.95% | 12.88% | 8.84% | -5.37% | 10.21% |
| Net Income Per EBT | 76.36% | 78.77% | 89.18% | 257.77% | 76.42% |
| EBT Per EBIT | 84.44% | 104.93% | 57.56% | -18.11% | 99.25% |
| Return on Assets (ROA) | 8.86% | 8.83% | 6.11% | -3.55% | 5.92% |
| Return on Equity (ROE) | 12.67% | 12.58% | 8.70% | -5.08% | 8.06% |
| Return on Capital Employed (ROCE) | 17.44% | 13.49% | 15.14% | 9.65% | 9.85% |
| Return on Invested Capital (ROIC) | 13.05% | 10.57% | 13.42% | 9.56% | 7.25% |
| Return on Tangible Assets | 10.86% | 10.64% | 7.57% | -4.60% | 8.25% |
| Earnings Yield | 7.33% | 6.39% | 5.11% | -3.41% | 5.55% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.16 | 4.06 | 3.34 | 2.60 | 2.67 |
| Payables Turnover | 3.51 | 3.70 | 5.13 | 4.47 | 4.49 |
| Inventory Turnover | 2.65 | 2.02 | 2.85 | 2.87 | 2.95 |
| Fixed Asset Turnover | 4.11 | 3.73 | 4.22 | 4.22 | 4.73 |
| Asset Turnover | 0.73 | 0.69 | 0.69 | 0.66 | 0.58 |
| Working Capital Turnover Ratio | 2.14 | 2.10 | 2.26 | 2.17 | 2.04 |
| Cash Conversion Cycle | 121.32 | 171.57 | 166.13 | 185.65 | 178.86 |
| Days of Sales Outstanding | 87.70 | 89.90 | 109.44 | 140.18 | 136.52 |
| Days of Inventory Outstanding | 137.65 | 180.42 | 127.88 | 127.17 | 123.61 |
| Days of Payables Outstanding | 104.03 | 98.76 | 71.20 | 81.70 | 81.27 |
| Operating Cycle | 225.35 | 270.33 | 237.32 | 267.35 | 260.14 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 174.78 | 132.77 | 198.01 | 95.88 | 115.17 |
| Free Cash Flow Per Share | 155.67 | 111.88 | 168.88 | 32.42 | 25.52 |
| Dividend Paid and CapEx Coverage Ratio | 3.25 | 2.23 | 3.22 | 1.00 | 0.96 |
| Capital Expenditure Coverage Ratio | 9.15 | 6.36 | 6.80 | 1.51 | 1.28 |
| Operating Cash Flow Coverage Ratio | 1.79 | 1.25 | 2.07 | 1.03 | 1.40 |
| Operating Cash Flow to Sales Ratio | 0.20 | 0.15 | 0.24 | 0.13 | 0.17 |
| Free Cash Flow Yield | 10.98% | 6.27% | 11.89% | 2.87% | 2.08% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 13.64 | 15.66 | 19.55 | -29.29 | 18.02 |
| Price-to-Sales (P/S) Ratio | 1.65 | 2.01 | 1.73 | 1.57 | 1.84 |
| Price-to-Book (P/B) Ratio | 1.73 | 1.97 | 1.70 | 1.49 | 1.45 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 9.11 | 15.96 | 8.41 | 34.86 | 48.08 |
| Price-to-Operating Cash Flow Ratio | 8.11 | 13.45 | 7.17 | 11.79 | 10.65 |
| Price-to-Earnings Growth (PEG) Ratio | 0.32 | 1.62 | -0.07 | 0.19 | 0.09 |
| Enterprise Value Multiple | 6.54 | 7.95 | 8.18 | 29.10 | 8.08 |
| Enterprise Value | 435.28B | 538.85B | 461.56B | 416.09B | 440.44B |
| EV to EBITDA | 6.54 | 7.95 | 8.18 | 29.10 | 8.08 |
| EV to Sales | 1.45 | 1.85 | 1.53 | 1.49 | 1.65 |
| EV to Free Cash Flow | 8.02 | 14.70 | 7.45 | 33.13 | 43.17 |
| EV to Operating Cash Flow | 7.14 | 12.39 | 6.35 | 11.20 | 9.57 |
| Tangible Book Value Per Share | 601.58 | 684.81 | 603.86 | 508.46 | 516.86 |
| Shareholders’ Equity Per Share | 821.11 | 906.49 | 834.19 | 758.81 | 844.19 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.24 | 0.21 | 0.11 | -1.58 | 0.24 |
| Revenue Per Share | 860.58 | 890.12 | 823.04 | 720.24 | 666.02 |
| Net Income Per Share | 104.00 | 114.06 | 72.62 | -38.58 | 68.08 |
| Tax Burden | 0.76 | 0.79 | 0.89 | 2.58 | 0.76 |
| Interest Burden | 0.98 | 0.96 | 0.78 | 1.97 | 0.97 |
| Research & Development to Revenue | 0.08 | 0.09 | 0.08 | 0.10 | 0.10 |
| SG&A to Revenue | 0.28 | 0.31 | 0.30 | 0.34 | 0.32 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.68 | 1.16 | 2.73 | -2.48 | 1.69 |
Currency in JPY
